Alvotech Quick Ratio (ALVO) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Alvotech  (NASDAQ: ALVO)

Alvotech's Quick Ratio

ALVO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Alvotech's Cash & cash equivalent, this led to improvement in Alvotech's Quick Ratio to 1.06, above Alvotech average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 123 other companies have achieved higher Quick Ratio than Alvotech in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 2314.

Explain Quick Ratio?
How much Cash & cash equivalents ALVO´s has?
What are ALVO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALVO Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 63.33 % 21.84 % -87.68 % 21.84 % -15.82 %
Y / Y Cash & cash equivalent Change 235.15 % 235.15 % 1283.88 % 235.15 % 360.95 %
Quick Ratio MRQ 1.06 0.14 1.16 0.14 0.52
ALVO's Total Ranking # 2314 # 0 # # #
Seq. Current Liabilities Change -87.08 % 868.59 % -89.68 % 1164.32 % -90.36 %
Seq. Cash & cash equivalent Change 0 % 13.8 % -12.13 % 235.15 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 124
Healthcare Sector # 680
Overall Market # 2314


Quick Ratio Statistics
High Average Low
2.82 0.48 0.01
0   0




Financial Statements
Alvotech's Current Liabilities $ 163 Millions Visit ALVO's Balance sheet
Alvotech's Cash & cash equivalent $ 172 Millions Visit ALVO's Balance sheet
Source of ALVO's Sales Visit ALVO's Sales by Geography


Cumulative Alvotech's Quick Ratio

ALVO's Quick Ratio for the trailling 12 Months

ALVO Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -12.74 % -15.19 % -19.34 % 64.7 % 62.74 %
Y / Y Cash & cash equivalent TTM Growth 304.61 % 338.23 % 403.82 % 113.22 % 75.89 %
Quick Ratio TTM 0.24 0.2 0.17 0.08 0.05
Total Ranking TTM # 4658 # 0 # # #
Seq. Current Liabilities TTM Growth 2.3 % 8.95 % -26.84 % 7.01 % -0.58 %
Seq. Cash & cash equivalent TTM Growth 22.08 % 28.34 % 49.1 % 73.19 % 32.23 %

Quick ratio ranking by company, industry and sector >> Back to ALVO Financial Strength Comparisons >> Go to Compare ALVO Quick Ratio to its Competitors

On the trailing twelve months basis ALVO Cash & cash equivalent more than doubled by 235.15 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Alvotech's Quick Ratio to 0.24, Quick Ratio remained below ALVO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 158 other companies have achieved higher Quick Ratio than Alvotech. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4658.

Explain Quick Ratio?
How much Cash & cash equivalents ALVO´s has?
What are ALVO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 159
Healthcare Sector # 1000
Within the Market # 4658


trailing twelve months Quick Ratio Statistics
High Average Low
0.57 0.29 0.04
(Dec 31 2025)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Vericel Corporation  2.80 $ 137.499  Millions$ 49.149  Millions
Argenx Se  2.76 $ 3,491.289  Millions$ 1,267.144  Millions
Humacyte Inc   2.75 $ 50.497  Millions$ 18.372  Millions
Mink Therapeutics Inc   2.67 $ 13.360  Millions$ 5.004  Millions
Cabaletta Bio Inc   2.66 $ 133.599  Millions$ 50.153  Millions
Cognition Therapeutics inc   2.64 $ 36.810  Millions$ 13.924  Millions
Exelixis Inc   2.61 $ 1,059.091  Millions$ 405.644  Millions
Twist Bioscience Corporation  2.54 $ 232.434  Millions$ 91.406  Millions
Adaptive Biotechnologies Corporation  2.52 $ 226.980  Millions$ 89.915  Millions
Jasper Therapeutics Inc   2.41 $ 28.692  Millions$ 11.887  Millions
Adma Biologics Inc   2.39 $ 87.630  Millions$ 36.595  Millions
C4 Therapeutics Inc   2.26 $ 74.603  Millions$ 33.032  Millions
Iovance Biotherapeutics inc   2.21 $ 296.980  Millions$ 134.315  Millions
Silexion Therapeutics Corp  2.18 $ 6.018  Millions$ 2.758  Millions
Passage Bio Inc   2.01 $ 46.303  Millions$ 23.083  Millions
Dyadic International Inc   1.99 $ 7.321  Millions$ 3.687  Millions
Armata Pharmaceuticals Inc   1.98 $ 8.688  Millions$ 4.383  Millions
Regenxbio Inc   1.95 $ 230.070  Millions$ 118.095  Millions
Exozymes Inc   1.94 $ 3.039  Millions$ 1.567  Millions
Sutro Biopharma Inc   1.88 $ 141.428  Millions$ 75.133  Millions
Neurocrine Biosciences Inc   1.82 $ 1,480.400  Millions$ 811.400  Millions
Sana Biotechnology Inc   1.76 $ 138.382  Millions$ 78.726  Millions
Elutia Inc   1.75 $ 36.350  Millions$ 20.739  Millions
Tarsus Pharmaceuticals Inc   1.72 $ 233.627  Millions$ 135.695  Millions
Novavax inc   1.60 $ 735.084  Millions$ 459.950  Millions
Dbv Technologies S a   1.47 $ 127.100  Millions$ 86.450  Millions
Calidi Biotherapeutics Inc   1.42 $ 5.600  Millions$ 3.935  Millions
Autolus Therapeutics Plc  1.41 $ 104.289  Millions$ 73.840  Millions
Champions Oncology Inc   1.41 $ 9.785  Millions$ 6.939  Millions
Biocryst Pharmaceuticals Inc   1.40 $ 274.948  Millions$ 196.066  Millions

Date modified: 2026-07-07T09:07:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.